Eli Lilly’s ongoing innovations could set the business up for a long time.
The company also has a strong dividend program.
Over the past decade, Eli Lilly (NYSE: LLY) has produced amazing returns, becoming the largest healthcare stock in the world in the process — and the first to hit a $1 trillion valuation. Lilly may not be able to maintain the pace it has set over the past 10 years, but it still has enough fuel to help turn patient investors into millionaires by the time they retire. Here’s why.
Lilly has performed well in recent years thanks to major breakthroughs, especially in diabetes and weight management. And although this area is the drugmaker’s main growth driver right now — and will remain so well into the 2030s — it is actively looking to diversify its lineup. The company is notably making a push into the large oncology field.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Patent cliffs for its current main products won’t come any time soon, but diversification will help Lilly navigate such losses when they do. Beyond any specific drug it is developing, it is also investing heavily in technology, including artificial intelligence (AI). The company is partnering with Nvidia to build the most powerful AI supercomputer in the pharmaceutical industry, as well as a research lab where its experts will work with AI engineers.
Management’s goal is to accelerate the discovery and development of breakthrough therapies. These initiatives won’t pay off immediately; they might not even make much of a dent in the next five years.
But they are helping set a solid foundation for the future, and that’s one thing long-term investors should focus on. Yes, Eli Lilly is posting excellent financial results right now, riding the wave of its best-selling drug, tirzepatide, approved for diabetes and weight management.
The company isn’t just sitting on its laurels, though. It is using that success and investing wisely in ways that will pay off a decade from now and beyond.
Eli Lilly does seem to have many of the qualities required to help make investors millionaires, given enough time — say, a few decades: Besides a solid business and an innovative culture, there’s its excellent dividend program — it has more than doubled its payouts in the past five years alone. Reinvesting the dividend will significantly boost total returns over the long run.
However, the key word here is “help,” as in, it likely can’t do it all by itself. Investors should ensure they have a relatively large, well-diversified portfolio. Eli Lilly can reasonably be one of the core holdings in such a portfolio, helping investors retire as happy multimillionaires.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 2, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
